s6y Altamira Therapeutics Ltd. 20-F

Altamira Therapeutics Ltd. 20-F, filed May 16, 2023: IDEA: XBRL DOCUMENT

Events after the balance sheet date (Details) - Non-adjusting events after reporting period [member]
1 Months Ended
May 12, 2023
SFr / shares
May 01, 2023
Apr. 17, 2023
$ / shares
shares
Apr. 13, 2023
Mar. 31, 2024
CHF (SFr)
Feb. 17, 2023
CHF (SFr)
SFr / shares
shares
Events after the balance sheet date (Details) [Line Items]            
Share capital (in Francs) | SFr           SFr 1,400,000
Divided common shares (in Shares) | shares           5,000,000
Common shares price           SFr 0.2
preference shares (in Shares) | shares           20,000,000
Preferred share price           SFr 0.02
Effective rate       90.00%    
Aggregate common shares (in Shares) | shares     4,341,012      
Average conversion price (in Dollars per share) | $ / shares     $ 1.4475      
Events after the balance sheet date description   the Company entered into a convertible loan agreement (the “2023 FiveT Loan Agreement”) with FiveT IM, pursuant to which FiveT IM has agreed to loan to the Company CHF 2,500,000, which bears interest at the rate of 10% per annum and matures 22 months from May 4, 2023. FiveT IM will have the right to convert all or part of the convertible loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT own no more than 4.99% of the common shares at any time. The conversion price was fixed at CHF 1.42 per common share (subject to adjustment for share splits or other similar events). Further, FiveT IM received warrants to purchase an aggregate of 1,625,487 common shares at an exercise price of CHF 1.538 per common share, which may be exercised up to five years.Commencing 60 days after May 4, 2023, but not before July 1, 2023 and subject to availability of an effective registration statement, the Company must repay at least 1/20th of the outstanding loan plus accrued interest pro rata in monthly tranches which, at the Company’s discretion, may be paid at any time during the month either in: (i) cash plus 3% or (ii) common shares, or a combination of both. Such shares will be priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date. The Company may prepay all or part of the convertible loan after three months.        
Convertible percentage         20.00%  
Cash proceeds (in Francs) | SFr         SFr 1,000,000  
September 2022 Loan Amendment [Member]            
Events after the balance sheet date (Details) [Line Items]            
Common shares price SFr 1.12          
Weighted average price percentage 120.00%          
Loan agreement description (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date, and lowered the strike price for the Warrants attached to the loan to CHF 0.881 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on trading day preceding the date of the September 2022 Loan Amendment.          
December 2022 Loan Amendment [Member]            
Events after the balance sheet date (Details) [Line Items]            
Common shares price SFr 0.881          
Common Shares [member]            
Events after the balance sheet date (Details) [Line Items]            
Divided common shares (in Shares) | shares           25,000,000
Common shares price           SFr 0.2
Divided amount (in Francs) | SFr           SFr 5,400,000
Additional common shares (in Shares) | shares           20,000,000
Additional common shares price           SFr 0.2
Preference shares [member]            
Events after the balance sheet date (Details) [Line Items]            
preference shares (in Shares) | shares           20,000,000
Preferred share price           SFr 0.02